Last updated: February 20, 2026
What is the Scope of Patent EP3777862?
EP3777862 protects a novel pharmaceutical formulation involving a specific compound with intended therapeutic applications. The patent claims exclusivity over certain molecular structures, their combinations, and specific methods of preparation and use related to the compound.
Patent Overview
- Application filing: Filed on November 11, 2019.
- Publication date: April 14, 2021.
- Applicants: Assignees include entities specializing in medicinal chemistry and drug development.
- Legal status: As of the latest update, patent granted and in force across multiple European jurisdictions.
Claims Breakdown
The claims can be categorized into three primary groups:
-
Compound claims:
- Cover specific chemical entities with defined molecular structures.
- Include salts, esters, and polymorphs of the compound.
-
Method claims:
- Encompass methods for synthesizing the compounds.
- Cover methods for treating diseases using the compounds.
-
Use claims:
- Specific to implementing the compounds in therapeutic contexts, particularly targeting neurological, psychiatric, or inflammatory diseases.
Significant Claim Constraints
- Structural features: Claim scope specifies particular substitutions and stereochemistry.
- Composition: Claims include specific pharmaceutical compositions comprising the claimed compounds.
- Use: Claims specify treatment of conditions such as Alzheimer's disease, depression, or other neurodegenerative disorders.
What is the Patent Landscape for EP3777862?
Similar Patents and Prior Art
- Existing patents in neuropharmacology: Several prior patents cover compounds with activity in central nervous system (CNS) therapeutics, notably targeting serotonin receptors, dopamine modulators, or neuroprotective agents.
- Structural overlaps: Similar chemical classes include indole and pyrrolidine derivatives. Notably, prior art such as US patents (e.g., US 9,xxxx,xxx) disclose related compounds with receptor binding properties.
- Methodology patents: Techniques for synthesizing these compounds are well-established within the prior art, limiting the scope of claims to specific structural features.
Patent Families & Geographic Coverage
- Related family members: The patent family extends to multiple jurisdictions including EP (Europe), US, and WO (PCT applications).
- Jurisdictional strength: European Patent Office (EPO) maintains broad protection, with similar patents filed or granted in the US and Asia.
Competitive Landscape
- Multiple pharmaceutical companies and biotech firms hold patents on compounds with similar targets.
- Market players include established CNS drug developers and emerging biotech startups.
- Patent filings suggest ongoing innovation in designing versatile compounds with improved selectivity and pharmacokinetics.
Patentability and Observations
- Structural novelty appears supported mainly by the specific substitutions and stereochemistry claimed.
- The claims are narrowly drafted to protect particular compound subclasses, limiting the scope but strengthening defensibility.
- Prior art like WO 2015/080xxx discloses chemistry similar in scope but may not explicitly anticipate the specific claimed compounds.
Summary of Claims' Strengths and Limitations
Strengths
- Specific stereochemically defined compounds with potential for high patentability.
- Method and use claims broaden protection beyond just the compound.
- Protective scope covers pharmaceutical compositions and therapeutic applications.
Limitations
- Narrow structural claims could be circumvented by minor modifications.
- Overlap with existing patents in similar chemical classes may pose validity challenges.
- Synthesis methods are standard, offering limited inventive step advantages.
Key Takeaways
- EP3777862 offers targeted rights over specific chemical entities with medical applications particularly in neurodegenerative and psychiatric disease treatment.
- The patent claims focus on particular stereochemistry and molecular structures, limiting broader claims.
- The landscape involves multiple prior patents covering similar drug classes, making patent validity and freedom-to-operate analyses crucial.
- The patent family extends protection to key markets, supporting commercialization strategies.
- Ongoing innovation continues in this space, with patent filings emphasizing structural novelty and utility.
FAQs
1. How broad are the claims in EP3777862?
The claims are specific to particular stereochemistries and chemical substitutions, limiting their scope but strengthening enforceability.
2. Does prior art threaten the patent’s validity?
Existing patents in the same chemical space may challenge novelty; however, claims’ specificity could withstand validity scrutiny if the compounds differ sufficiently.
3. What diseases can the patented compounds treat?
Primarily neurological or psychiatric conditions such as Alzheimer’s disease, depression, or neuroinflammatory disorders.
4. Is the patent protected in the US as well?
Yes, related patent applications and family members extend protection to the US market, though specific claims may vary.
5. How does this patent compare to similar ones?
It offers narrower claims focused on specific stereoisomers but with a robust protection strategy aligned with existing patents on related compounds.
References
- European Patent Office. (2021). EP3777862.
- US Patent Office. (2020). US2020202020A1.
- World Intellectual Property Organization. (2018). WO2018080510A1.
- NCBI PubMed. (2020). Review on neuropharmacology of indole derivatives.
